secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2023-10-20T23:59:59+00:00
Accession:  0001601485-23-000065
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics announces departure of Chief Business Officer Annette Matthies effective Oct 19, 2023
--------------------------------------------------------------------------------

- Annette Matthies, Ph.D. ceased as Chief Business Officer; separation agreement signed October 19, 2023.
- Company will pay six months of base salary and reimburse COBRA premiums for up to six months.
- Separation includes standard release of claims and confidentiality covenants.
- No replacement or successor has been named; reason for departure not disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000065/0001601485-23-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000065/angn-20231019.htm
  HTML page:      https://secwatch.observer/filing/0001601485-23-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer